Arcturus Therapeutics
ARCT
124 hedge funds and large institutions have $187M invested in Arcturus Therapeutics in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 47 increasing their positions, 36 reducing their positions, and 23 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 36
28% more capital invested
Capital invested by funds: $146M → $187M (+$41M)
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
14% more call options, than puts
Call options by funds: $1.79M | Put options by funds: $1.57M
3% more funds holding
Funds holding: 120 → 124 (+4)
2.06% more ownership
Funds ownership: 83.4% → 85.46% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$3.9M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$1.91M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$1.91M |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.87M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$2.91M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.47M |
| 3 |
Goldman Sachs
New York
|
-$1.4M |
| 4 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$1.24M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.16M |
ARCT Hedge Fund Activity: Q1 2026 in Review
124 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2026, worth a combined $187M — up 28% from $146M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ARCT positions and 23 closed out — a net gain of 5 holders — while 47 added to existing stakes and 36 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $3.9M. The largest seller was Jane Street, cutting an estimated $2.91M.
- 124 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2026, up from 120 in Q4 2025.
- Funds reported $187M of Arcturus Therapeutics stock for Q1 2026, up 28% quarter-over-quarter.
- 28 funds opened new Arcturus Therapeutics positions in Q1 2026 and 23 closed out, a net change of +5 holders.
- The largest Arcturus Therapeutics buyer in Q1 2026 was Two Sigma Investments, an estimated $3.9M added.
- The largest Arcturus Therapeutics seller in Q1 2026 was Jane Street, an estimated $2.91M sold.
Based on aggregated 13F filings for Q1 2026.